Loading
Latest filing published 15 Apr 2025 for Humacyte, Inc., €8,818.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of William John Scheessele in Humacyte, Inc., where the filings describe the role as senior executive. We count 3 filings; the first trade dates from 24 May 2022 and the latest from 14 April 2025.
On the market, this insider has only ever bought: 3 purchases, €70k in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2025, the count stands at 1 purchase and no sales.
In size, the median ticket on the buying side is €15k. 2 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster.
The newest entry dates from 15 April 2025: an open-market purchase of €8,818, in Humacyte, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations